Tamibarotene is under clinical development by Syros Pharmaceuticals and currently in Phase II for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase II drugs for Refractory Acute Myeloid Leukemia have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tamibarotene’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tamibarotene overview
Tamibarotene (Amnolake) is a synthetic retinoid acts as anti-neoplastic agent. It is formulated as tablets for oral route of administration. It is used for the treatment of relapsed or refractory acute promyelocytic leukemia.
It is under development for autosomal dominant polycystic kidney disease (ADPKD), relapsed and refractory, newly diagnosed acute myelocytic leukemia, myelodysplastic syndrome, neutropenia, neuroblastoma, germ cell tumor and sarcomas . It was also under development for acute promyelocytic leukemia in the U.S. and EU , breast cancer and hepatocellular carcinoma, acute promyelocytic leukemia in China, chronic myelomonocytic leukemia.
Syros Pharmaceuticals overview
Syros Pharmaceuticals (Syros) is a biopharmaceutical company that develops medicines for the treatment of cancer, immune-mediated diseases, and other diseases. The company offers its pipeline products under clinical trials including Tamibarotene, an oral potent and selective RARa agonist targets acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); SY-2101, a arsenic trioxide (ATO) for the treatment of acute promyelocytic Leukemia; SY-5609, a highly selective and potent oral inhibitor treats pancreatic cancer and BRAFT-mutant colorectal cancer. It offers services such as gene regulation, research and drug development, drug discovery, clinical trials among others. Syros is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of Tamibarotene’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
